Exchange Traded Concepts LLC Acquires 7,943 Shares of Lantheus Holdings, Inc. $LNTH

Exchange Traded Concepts LLC increased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 98.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,994 shares of the medical equipment provider’s stock after purchasing an additional 7,943 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Lantheus were worth $820,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Elevation Point Wealth Partners LLC acquired a new stake in Lantheus during the 2nd quarter worth $26,000. Osterweis Capital Management Inc. bought a new position in Lantheus during the 2nd quarter worth about $36,000. Quarry LP raised its position in Lantheus by 2,350.0% in the 1st quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock valued at $48,000 after buying an additional 470 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Lantheus by 190.2% in the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock valued at $87,000 after purchasing an additional 698 shares during the last quarter. Finally, EMC Capital Management acquired a new stake in Lantheus in the 2nd quarter valued at $93,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LNTH has been the topic of a number of analyst reports. TD Cowen dropped their price objective on Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, September 15th. B. Riley cut their price objective on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a research report on Tuesday, September 16th. Mizuho boosted their target price on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Truist Financial boosted their price target on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Finally, Weiss Ratings downgraded shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $78.00.

Lantheus Trading Up 0.0%

NASDAQ LNTH opened at $66.71 on Monday. The business’s 50-day moving average price is $58.96 and its two-hundred day moving average price is $62.10. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $111.29. The firm has a market capitalization of $4.42 billion, a PE ratio of 28.03 and a beta of -0.10. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 EPS for the quarter. The business had revenue of $92.51 million for the quarter. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. On average, analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.